Seaport Therapeutics, Inc.
BioSniper AI · SPTX
Seaport Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel medicines for central nervous system disorders, with lead candidates GlyphAllo for major depressive disorder and GlyphAgo for generalized anxiety disorder.
Key risk: Clinical trial failure risk
Spotter reads the filings and answers with citations.
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Seaport Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel medicines for central nervous system disorders, with lead candidates GlyphAllo for major depressive disorder and GlyphAgo for generalized anxiety disorder.
- Seaport is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients [sec · filed 2026-04-10].
- As of March 31, 2026, the company had cash, cash equivalents and investments of $212.6 million, and believes this together with IPO net proceeds will fund operations into 2029 [sec_mda · as of 2026-06-08].
- The company reported a net loss of $25.4 million for the three months ended March 31, 2026, and an accumulated deficit of $139.5 million as of that date [sec_mda · as of 2026-06-08].
- Seaport's business is highly dependent on the success of its product candidates, particularly GlyphAllo for MDD and GlyphAgo for GAD and MDD [sec · filed 2026-04-10].
- The company has not generated any revenue from product sales and does not expect to do so unless and until it obtains regulatory approval, which may not be for at least several years [sec_mda · as of 2026-06-08].
What works
- Seaport's cash position of $212.6 million as of March 31, 2026, combined with IPO proceeds, is projected to fund operations into 2029, providing a multi-year runway for clinical development [sec_mda · as of 2026-06-08].
- The company's Glyph platform is designed to enable the development of new medicines, potentially offering a differentiated approach to CNS therapies [sec_mda · as of 2026-06-08].
What to weigh
- Seaport has a history of losses, with a net loss of $25.4 million in Q1 2026 and an accumulated deficit of $139.5 million as of March 31, 2026 [sec_mda · as of 2026-06-08].
- The company is highly dependent on the success of its lead candidates GlyphAllo and GlyphAgo, and failure in clinical trials would materially harm the business [sec · filed 2026-04-10].
- Seaport has no approved products or revenue, and expects to incur significant expenses for the foreseeable future, requiring additional funding if current plans change [sec_mda · as of 2026-06-08].
From the filings
Quoted directly from source documents.
Seaport is a clinical-stage therapeutics company
“We are a clinical-stage therapeutics company focused on inventing and developing new medicines for pa”
SEC MD&A · April 10, 2026
Cash position and runway into 2029
“As of March 31, 2026, we had cash, cash equivalents and investments of $212.6 million. Based on our current operating plans, we believe that our existing cash, cash equivalents and investments, together with the net proceeds from our IPO completed during the second quarter of 2026, will be sufficient to fund our operating expenses and capital expenditure requirements into 2029.”
SEC MD&A · June 8, 2026
Net loss and accumulated deficit
“2026 and 2025, we had a net loss of $25.4 million and $13.1 million, respectively. As of March 31, 2026, we had an accumulated deficit of $139.5 million.”
SEC MD&A · June 8, 2026
Dependence on lead candidates
“Our business is highly dependent on the success of our product candidates, particularly GlyphAllo for the treatment of MDD with or without anxious distress and GlyphAgo for the treatment of generalized anxiety disorder, or GAD, and MDD.”
SEC filings · April 10, 2026
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — If later-stage trials do not show adequate efficacy and safety, regulatory approval will be adversely impacted [sec · filed 2026-04-10].
- No revenue or approved products — Seaport has no product revenue and does not expect any for at least several years, if ever [sec_mda · as of 2026-06-08].
- Need for additional financing — The company may require additional funding to complete development, and failure to raise capital could force delays or cuts [sec · filed 2026-04-10].
- Dependence on third parties — Seaport relies on third parties to conduct clinical trials and manufacture product candidates [sec · filed 2026-04-10].
What to watch
- Initiation and progress of clinical trials for GlyphAllo and GlyphAgo [sec · filed 2026-04-10].
- Updates on the effectiveness of the Glyph platform in enabling new candidates [sec_mda · as of 2026-06-08].
- Cash burn rate and any need for additional financing beyond the projected runway [sec_mda · as of 2026-06-08].
- Regulatory milestones and interactions with the FDA for lead programs [sec · filed 2026-04-10].
Sources: SEC filings · SEC MD&A · Generated July 14, 2026 · How we verify sources →
Unlock the full Seaport Therapeutics, Inc. dossier
Sign in free to see catalysts, full pipeline, financials, FDA decisions, news, and run live AI deep-dives.
Free account includes:
- Full pipeline, catalysts, financials & FDA decisions for Seaport Therapeutics, Inc.
- 200 free AI credits / month to run live Spotter deep-dives
- Watchlist, news alerts & the biotech event calendar
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
26.5 months
OCF -$20M · Net income -$25M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Frequently asked questions
What is the AI investment thesis for Seaport Therapeutics, Inc.?
Seaport Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel medicines for central nervous system disorders, with lead candidates GlyphAllo for major depressive disorder and GlyphAgo for generalized anxiety disorder.
Who is the CEO of Seaport Therapeutics, Inc.?
Ms. Daphne Zohar is the chief executive officer of Seaport Therapeutics, Inc. (SPTX).
Where is Seaport Therapeutics, Inc. headquartered?
Seaport Therapeutics, Inc. (SPTX) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on Seaport Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.